TACR1 and central nervous system cancer: A properly chosen vector (in the case of gliomas, the neuropeptide substance P) that has a high affinity for an overexpressed receptor (on the glioma cells, neurokinin-1 receptors) concentrates the therapeutic radionuclide around the target point.